C21 Investments Inc
C21 Investments Inc., an integrated cannabis company, cultivates, processes, distributes, and sells cannabis and hemp-derived consumer products in the United States. The company offers CO2, live resin, distillate, CBD cured resin, and CBD CO2 vaporizer pens; live, cured, and CBD cured resin extracts; bulk and packaged flowers; edibles; pre-rolls; tinctures; and topicals. It also provides payroll … Read more
C21 Investments Inc (CXXIF) - Net Assets
Latest net assets as of October 2025: $26.84 Million USD
Based on the latest financial reports, C21 Investments Inc (CXXIF) has net assets worth $26.84 Million USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($54.89 Million) and total liabilities ($28.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $26.84 Million |
| % of Total Assets | 48.89% |
| Annual Growth Rate | N/A |
| 5-Year Change | 13.17% |
| 10-Year Change | N/A |
| Growth Volatility | 10511.07 |
C21 Investments Inc - Net Assets Trend (2015–2025)
This chart illustrates how C21 Investments Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for C21 Investments Inc (2015–2025)
The table below shows the annual net assets of C21 Investments Inc from 2015 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-01-31 | $28.68 Million | -7.64% |
| 2024-01-31 | $31.05 Million | -9.52% |
| 2023-01-31 | $34.32 Million | -1.91% |
| 2022-01-31 | $34.98 Million | +38.06% |
| 2021-01-31 | $25.34 Million | +86.59% |
| 2020-01-31 | $13.58 Million | -35.60% |
| 2019-01-31 | $21.09 Million | +30049.36% |
| 2018-01-31 | $69.94K | +119.78% |
| 2017-01-31 | $-353.57K | +10.43% |
| 2016-01-31 | $-394.72K | -29.00% |
| 2015-01-31 | $-305.99K | -- |
Equity Component Analysis
This analysis shows how different components contribute to C21 Investments Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5999800400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $105.50 Million | 367.89% |
| Total Equity | $28.68 Million | 100.00% |
C21 Investments Inc Competitors by Market Cap
The table below lists competitors of C21 Investments Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
5th Planet Games A/S
OTCQB:IDGAF
|
$14.73 Million |
|
Cybertech Systems And Software Limited
NSE:CYBERTECH
|
$14.73 Million |
|
Strategic Investments A/S
CO:STRINV
|
$14.74 Million |
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
$14.74 Million |
|
Sentien Printing Factory Co Ltd
TWO:8410
|
$14.72 Million |
|
Wentel Engineering Holdings Berhad
KLSE:0298
|
$14.72 Million |
|
Telecoms & Informatics JSC
VN:ICT
|
$14.72 Million |
|
Fodelia
HE:FODELIA
|
$14.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in C21 Investments Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 31,047,008 to 28,675,777, a change of -2,371,231 (-7.6%).
- Net loss of 3,969,542 reduced equity.
- Other factors increased equity by 1,598,311.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.97 Million | -13.84% |
| Other Changes | $1.60 Million | +5.57% |
| Total Change | $- | -7.64% |
Book Value vs Market Value Analysis
This analysis compares C21 Investments Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.58x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 12.13x to 0.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-01-31 | $0.01 | $0.14 | x |
| 2019-01-31 | $0.36 | $0.14 | x |
| 2020-01-31 | $0.15 | $0.14 | x |
| 2021-01-31 | $0.22 | $0.14 | x |
| 2022-01-31 | $0.29 | $0.14 | x |
| 2023-01-31 | $0.29 | $0.14 | x |
| 2024-01-31 | $0.26 | $0.14 | x |
| 2025-01-31 | $0.24 | $0.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently C21 Investments Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.18%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.99x
- Recent ROE (-13.84%) is above the historical average (-114.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-67.35K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-55.51K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.00K |
| 2018 | -896.56% | 0.00% | 0.00x | 3.98x | $-634.05K |
| 2019 | -111.92% | -912.82% | 0.03x | 3.67x | $-25.71 Million |
| 2020 | -239.74% | -86.34% | 0.61x | 4.53x | $-33.91 Million |
| 2021 | -24.10% | -16.90% | 0.53x | 2.72x | $-8.64 Million |
| 2022 | 31.20% | 33.10% | 0.53x | 1.77x | $7.42 Million |
| 2023 | 0.85% | 1.01% | 0.50x | 1.70x | $-3.14 Million |
| 2024 | -10.65% | -11.69% | 0.52x | 1.76x | $-6.41 Million |
| 2025 | -13.84% | -13.18% | 0.53x | 1.99x | $-6.84 Million |
Industry Comparison
This section compares C21 Investments Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| C21 Investments Inc (CXXIF) | $26.84 Million | 0.00% | 1.05x | $14.73 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |